Navigation Links
New PAREXEL Report Defines The Next Generation Of Strategic Partnerships Between CROs And Biopharmaceutical Industry
Date:4/22/2013

BOSTON, April 22, 2013 /PRNewswire/ -- PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today released a new research report called Strategic Partnerships 2013 at the 22nd Annual Partnerships in Clinical Trials Conference in Orlando, FL. The report is the first to explore the current outsourcing landscape and the value Strategic Partnerships provide to biopharmaceutical companies of all sizes. Strategic Partnerships are multi-year, highly-integrated engagements between biopharmaceutical companies and clinical research organizations (CROs).

The report found that 85% of biopharmaceutical industry executives interviewed and who were engaged in Strategic Partnerships, believe that the relationship between their companies and CROs were positively impacted. Executives believe this more integrated approach to clinical development reduces their level of oversight, decreases fixed costs and provides them with access to capabilities not found internally. 

"Strategic Partnerships 2013 highlights the growing importance to biopharmaceutical companies of engaging in Strategic Partnerships to drive greater value through seamless integration, aligned goals and mutual investment," said Josef von Rickenbach , Chairman of the Board and Chief Executive Officer of PAREXEL International. "The report also illustrates that there are further benefits of Strategic Partnerships that can be generated through additional joint focus on cycle times, shared expertise and efficient oversight models."

The industry executives interviewed for this report believe Strategic Partnerships are transforming the way new therapies are developed and commercialized. However, they also noted that the model must evolve to adequately and effectively meet the challenges of a constantly changing regulatory environment. When asked about the vision for the next-generation of Strategic Partnerships, the respondents identified increased alignment in commercial incentives, deeper team collaboration (strategic and targeted expertise) and faster time-to-market through improved cycle times as the top three areas. 

Later this week at the Annual Partnerships conference (Wednesday, April 24), Mr. von Rickenbach will serve as a panelist at a session/roundtable titled, "Wall Street Leadership Panel on the Economic Outlook for Pharma in 2013 - Opportunities, Investment Areas and Effects on the Outsourcing Industry."  As part of his presentation, he will discuss the benefits and implications of Strategic Partnerships based on PAREXEL's experience, and the CRO industry's future outlook.

About Strategic Partnerships 2013
For the report, Booms Research & Consulting, Inc. - an independent research firm conducted in-depth interviews among senior-level executives such as C-suite leaders as well as heads of clinical operations, R&D, and strategic outsourcing, representing global biopharmaceutical companies (n=26). The sample size included: 71% large pharmaceutical companies, 12% mid-sized pharmaceutical companies, and 17% small biopharmaceutical companies. The interviews were conducted in English in the fall 2012. Participants represent companies with 39% of industry R&D spend. The report included both quantitative and qualitative questions to better understand the current state of clinical development outsourcing and strategic partnerships. The survey includes both single and multiple response questions. As such, some percentages will exceed 100%.

For a full copy of the report, please visit www.PAREXEL.com

About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 73 locations throughout 51 countries around the world, and has approximately 14,000 employees. For more information about PAREXEL International visit www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2012 as filed with the SEC on February 1, 2013, which "Risk Factors" discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

© 2013 PAREXEL International Corporation.  PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a registered trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.Contacts: Diana Martin, Vice President Corporate Communications

Katie HeplerPAREXEL International

Ogilvy Public RelationsTel: +1 781-434-5516

Tel: +1 212-880-5220Email: Diana.Martin@PAREXEL.com

 

Email: Katie.Hepler@ogilvy.comKim LeadleyPAN CommunicationsTel: +1 617-502-4300Email: PAREXEL@pancomm.com
'/>"/>

SOURCE PAREXEL International
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PAREXEL International Provides Update On Share Repurchase Program, Announces A New $50 Million Accelerated Share Repurchase Agreement And A New $50 Million 10b5-1 Trading Plan
2. PAREXEL International To Present At Raymond James Investors Conference And Barclays Capital Healthcare Conference
3. PAREXEL International To Present At Citi Global Healthcare Conference
4. PAREXEL International Reports Second Quarter Fiscal Year 2013 Results
5. PAREXEL International To Present At Oppenheimer Healthcare Conference
6. PAREXEL International To Present At Lazard Capital Healthcare Conference And Jefferies Global Healthcare Conference
7. PAREXEL and Salem State University Launch Clinical Trial Management Graduate Program
8. PAREXEL International to Present at Robert Baird Healthcare Conference
9. PAREXEL Strengthens Outcomes Research Capabilities To Help Biopharma Meet Commercialization Goals
10. PAREXEL Launches The PAREXEL BioPharm Unit To Meet The Critical Development Goals Of Small And Mid-Sized Biopharmaceutical Companies
11. PAREXEL And Korea Drug Development Fund Announce Alliance To Accelerate Global Drug Development And Commercialization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... 2016 The World Health Organization (WHO) expanded the ... include adolescents aged 13 years, and above. Effective immediately, the ... adult and adolescent males in the 14 priority countries in ... the first male circumcision device to receive WHO Prequalification on ... Horowitz said: " The expanded use of ...
(Date:5/23/2016)... SAN FRANCISCO , May 23, 2016 ... expected to reach USD 5.0 billion by 2022, according ... The increasing generation of medical waste coupled with the ... healthcare industry is expected to drive the demand for ... with these devices as compared to that of the ...
(Date:5/20/2016)... YORK , May 20, 2016 ... many veteran investors believe that the industry is not ... space, and today ActiveWallSt.com featured the following four equities: ... Inc. (NASDAQ: ATHX ), Aralez Pharmaceuticals Inc. ... (NASDAQ: INFI ). Sign up for your ...
Breaking Medicine Technology:
(Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... According to an article published ... a massive role in oral health and hygiene. The article points out that, as long ... on their toothbrushes will become worn and frayed. Of course, these worn-out bristles won’t clean ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... aggression and sexual objectification, according to Georgia State University researchers. , ... girls in the fifth, sixth and seventh grades shared their experiences with ...
(Date:5/23/2016)... ... May 23, 2016 , ... California State ... discriminated minorities’ quality of life and is currently focusing on ways to improve ... to be tested through research to find out whether watching them could have ...
(Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... ... provider of distance education worldwide for people who are blind or visually impaired, ... 10-year tenure of retiring President Charles E. Young. Hadley’s Board of Trustees retained ...
(Date:5/23/2016)... ... 23, 2016 , ... Overweight and obesity in children can be hard on ... most of all, it can be hard on the child carrying excess weight. And ... a dint in childhood obesity statistics or making it easier for overweight children to ...
Breaking Medicine News(10 mins):